Michael J. Welch was a key driver in developing methods to produce NCA radiometals for imaging and therapy, including novel targetry, separation, purification, quality control, and target recycling techniques. His impact is seen in the production of NCA radiometals at numerous sites and in the development of new �theranostic agents.� A brief overview will be presented highlighting Michael Welch's work and his impact on NCA radiometal development at MURR, including the NCA radiolanthanide Lu-177, which is currently used in clinical applications. Lutetium-177 attached to small molecules, peptides and antibodies has seen increased use for therapeutic and diagnostic applications due to its favorable nuclear properties (7 d half-life, ~0.5 MeV �-, 208 keV ? (11%)). Indirect irradiation of Yb-176 yields a high specific activity Lu-177 (110 Ci/mg) that is easily incorporated into DOTA and DTPA chelates, and its long half-life allows for distribution to remote regions.

Development of NCA radiometals for imaging and therapy

245th National Meeting (2013)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.